Robert L Wortmann1. 1. Department of Internal Medicine, University of Oklahoma College of Medicine, Tulsa, Oklahoma 74135, USA. Robert-wortmann@ouhsc.edu
Abstract
PURPOSE OF REVIEW: To review the recent advances in the management of gout and hyperuricemia. RECENT FINDINGS: The first quality indicators for gout management have been proposed. Selective COX II inhibitors, as well as traditional NSAIDs, are effective in acute gout. A new xanthine oxidase inhibitor, febuxostat, and pegylated uricases are in clinical trials. SUMMARY: The therapeutic aims in gout include termination of the acute attack as promptly and gently as possible, prevention of future attacks, prevention or reversal of complications of the, and prevention or reversal of associated features such as obesity, hypertriglyceridemia, hypertension, or alcoholism.
PURPOSE OF REVIEW: To review the recent advances in the management of gout and hyperuricemia. RECENT FINDINGS: The first quality indicators for gout management have been proposed. Selective COX II inhibitors, as well as traditional NSAIDs, are effective in acute gout. A new xanthine oxidase inhibitor, febuxostat, and pegylated uricases are in clinical trials. SUMMARY: The therapeutic aims in gout include termination of the acute attack as promptly and gently as possible, prevention of future attacks, prevention or reversal of complications of the, and prevention or reversal of associated features such as obesity, hypertriglyceridemia, hypertension, or alcoholism.
Authors: Tim L Jansen; Pascal Richette; Fernando Perez-Ruiz; Anne-Kathrin Tausche; Philip-André Guerne; Leonardo Punzi; Burkhard Leeb; Victoria Barskova; Till Uhlig; José Pimentão; Irena Zimmermann-Górska; Elisio Pascual; Thomas Bardin; Michael Doherty Journal: Clin Rheumatol Date: 2010-04-17 Impact factor: 2.980
Authors: Theodora Szasz; A Elizabeth Linder; Robert P Davis; Robert Burnett; Gregory D Fink; Stephanie W Watts Journal: J Cardiovasc Pharmacol Date: 2010-12 Impact factor: 3.105